Nov 12, 2024 4:05 pm EST Eyenovia Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Oct 23, 2024 7:00 am EDT Eyenovia Announces Publication of Study Demonstrating Favorable Impact on the Ocular Surface of Medication Delivered with the Optejet®
Oct 16, 2024 7:00 am EDT Eyenovia Announces Presentation of Phase 3 Clobetasol Study Results at the American Academy of Ophthalmology (AAO) 2024 Expo
Oct 1, 2024 7:00 am EDT Eyenovia Announces Commencement of Manufacturing of its Advanced, Second Generation Optejet Device
Sep 26, 2024 7:00 am EDT Eyenovia Announces Launch and Commercial Availability of Clobetasol Propionate Ophthalmic Suspension 0.05% for Post-Operative Inflammation and Pain Following Ocular Surgery
Sep 5, 2024 7:00 am EDT Eyenovia Announces Taiwan Export License Approval to Commence Shipment of Clobetasol Propionate Ophthalmic Suspension (0.05%) to the U.S.